1st Edition

Development and Application of Biomarkers

By Roger L. Lundblad Copyright 2011
    300 Pages 9 B/W Illustrations
    by CRC Press

    297 Pages 9 B/W Illustrations
    by CRC Press

    Continue Shopping

    First introduced to biomedical research in 1980, the term biomarker has taken on a life of its own in recent years and has come to mean a number of things. In biomedical science, biomarker has evolved to most commonly mean a characteristic that can be used either as a diagnostic or a prognostic, but most significantly as a screening indicator for pathologies that tend to be somewhat silent prior to overt clinical display.

    Applying scientific rigor, as well as a disciplined approach to nomenclature, Roger Lundblad’s Development and Application of Biomarkers rationalizes the current enthusiasm for biomarkers with the use of well-established clinical laboratory analytes in clinical medicine. Highly respected for his work as both a classical protein scientist and as a pioneer in proteomics, Dr. Lundblad catalogs various biomarkers recognized in clinical medicine and, where possible, matches the expectations for advances in screening technologies with the realities of statistical analysis. More specifically, this important reference:

    • Details an extensive list of biomarkers for various stages of a number of cancer types including ovarian, pancreatic, prostate, and breast cancer
    • Looks at how proteomics is used for the discovery and validation of biomarkers
    • Explores the use of microarray technology, ultra-high performance liquid chromatography, and computational bioinformatic approaches for the discovery and use of biomarkers
    • Examines the use of cells and cell fragments as more complex biomarkers
    • Organizes a host of significant biomarkers and essential research by type and use in a series of readily accessible tables

    Throughout this volume, Dr. Lundblad encourages consideration of biomarkers more as a concept than as laboratory analytes, emphasizing the relation between the discovery of a biomarker and the biology underlying its production. Ultimately, it is a thorough understanding of that underlying biology that will lead to the development of assays that are robust and reproducible, as well as clinically significant.

    Introduction to Biomarkers
    Application of Biomarkers in Diagnostics, Prognostics, Theranostics, and Personalized Medicine
    Biomarkers and Diagnostics
    Biomarkers and Screening
    Biomarkers and Prognosis
    Biomarkers and Theranostics and Personalized Medicine
    Biomarkers and Specific Pathologies
    Rheumatoid Arthritis
    Inflammation Biomarkers in Different Pathologies
    Biomarkers in Ophthalmology
    Biomarkers in Neurology
    Cardiac Biomarkers
    Biomarkers in Renal Disease
    Biomarkers for Bone
    Biomarkers for Exposure to Environmental Toxins
    Biomarkers and the Development of Biopharmaceuticals
    Development of Biomarkers for Oncology
    Intermediate Biomarkers and the Precancerous Condition
    Cancer and Inflammation
    Head and Neck Cancer
    Ovarian Cancer
    Pancreatic Cancer
    Prostate Cancer
    Breast Cancer
    The Use of Proteomics to Discover Biomarkers
    Miscellaneous Biological Fluids/Excretory Products as Sources of Biomarkers
    Biomarkers in Tissue Samples
    Modified Proteins, Oligosaccharides, and Oligonucleotidesas Biomarkers
    Complex Biomarkers: Cells, Cell Membrane Proteins, and Cell Fragments as Biomarkers
    Use of Microarray Technology in Biomarker Discovery and Development
    Development of Assays for Biomarkers
    Appendix A: Model Standard Operating Procedure for an Assay

    references provided at the end of every chapter


    Roger L. Lundblad is a highly accomplished expert in protein science and proteomics. He is well known for the rigorous application of classical protein science to more modern approaches and the development of a wealth of viable and practical applications. Dr. Lundblad is a native of San Francisco, California. He received his undergraduate education at Pacific Lutheran University and his Ph.D. degree in biochemistry at the University of Washington. After post-doctoral work in the laboratories of Stanford Moore and William Stein at the Rockefeller University, he joined the faculty of the University of North Carolina at Chapel Hill in 1968 attaining the rank of Full Professor in 1976 He joined the Hyland Division of Baxter Healthcare in 1990.

    Currently Dr. Lundblad is an independent consultant and writer in biotechnology in Chapel Hill, North Carolina. He is an adjunct Professor of Pathology at the University of North Carolina at Chapel Hill and Editor-in-Chief of the Internet Journal of Genomics and Proteomics. He has authored and edited numerous books that focus both on advances in proteomics and modern applications as well as on the fundamentals of protein science. He recently co-edited Handbook of Biochemistry and Molecular Biology, Fourth Edition.